A safe and effective method to treat psoriatic arthritis with anti-IL23 specific antibodies
JP2024510744A5Pending Publication Date: 2025-03-18JANSSEN BIOTECH INC
0 Cites 0 Cited by
Patent Information
- Application Number
- JP2023555570
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-03-12
- Filing Date
- 2022-03-10
- Publication Date
- 2025-03-18
AI Technical Summary
Technical Problem
Current treatments for psoriatic arthritis often have limited efficacy and safety, and there is a need for targeted therapies that specifically inhibit IL-23 without affecting IL-12, as both cytokines share a common subunit, leading to unclear disease mediation.
Method used
Administering anti-IL-23 specific antibodies, such as guselkumab, subcutaneously every 4 or 8 weeks, to treat psoriatic arthritis, achieving significant improvement in disease activity without adverse events.
Benefits of technology
The method results in at least a 20% improvement in the American College of Rheumatology Core Set Disease Index (ACR20) with minimal adverse events, effectively managing psoriatic arthritis symptoms and reducing disease progression.
✦ Generated by Eureka AI based on patent content.
Abstract
A method of treating psoriatic arthritis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in an amount clinically proven to be safe and clinically proven to be effective, wherein the patient achieves significant ACR20 / 50 / 70, IGA, HAQ-DI, CRP, SF-36 PCS / MCS, MDA, VLDA, enthesitis, dactylitis, and LEI / dactylitis improvements as measured at 16, 24, 52, and / or 100 weeks after initial treatment.
Need to check novelty before this filing date? Find Prior Art